Compare PTLE & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTLE | CDIO |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 5.3M |
| IPO Year | 2024 | N/A |
| Metric | PTLE | CDIO |
|---|---|---|
| Price | $0.15 | $3.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 26.2K |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $91,415,732.00 | $15,782.00 |
| Revenue This Year | N/A | $1,434.82 |
| Revenue Next Year | N/A | $4,661.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.14 | $2.42 |
| 52 Week High | $15.78 | $53.10 |
| Indicator | PTLE | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 57.54 |
| Support Level | $0.15 | $2.85 |
| Resistance Level | $0.17 | $3.13 |
| Average True Range (ATR) | 0.01 | 0.35 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 3.67 | 100.00 |
PTL Ltd is a holding company. Through its subsidiaries, it is an established bunkering facilitator providing marine fuel logistics services for vessel refuelling, serving the Asia Pacific market. The company's services mainly involve facilitating with its suppliers to supply fuel for the use by the customers' vessels at various ports along their voyages in the Asia Pacific region; arranging vessel refuelling activities at competitive pricing to the customers; offering trade credit to the customers for vessel refuelling; handling unforeseeable circumstances faced by the customers and providing contingency solutions to the customers on time; and handling disputes, mainly concerning quality and quantity issues on marine fuel. The company derives its maximum revenue from Hong Kong.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.